

CITATION REPORT

List of articles citing

Dual PPAR α / γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

DOI: 10.1111/liv.13634

Liver International, 2018, 38, 1084-1094.

Source: <https://exaly.com/paper-pdf/69652108/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
122	Dual PPAR α / γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. <i>Liver International</i> , 2018 , 38, 1084-1094	7.9	90
121	Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis. 2018 , 67, 2485-2493		52
120	An update on the recent advances in antifibrotic therapy. 2018 , 12, 1143-1152		45
119	Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation. 2018 , 75, 2951-2961		36
118	The Active Components of Fuzheng Huayu Formula and Their Potential Mechanism of Action in Inhibiting the Hepatic Stellate Cells Viability - A Network Pharmacology and Transcriptomics Approach. 2018 , 9, 525		11
117	Insights into the Role of PPAR α in NAFLD. 2018 , 19,		29
116	The dual PPAR α / γ agonist saroglitazar ameliorates thioacetamide-induced liver fibrosis in rats through regulating leptin. 2019 , 392, 1569-1576		14
115	Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2 α /PPAR α pathway. 2019 , 317, E710-E722		37
114	Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease. 2019 , 9, 731-739		29
113	New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. 2019 , 18, 80		55
112	The PPAR-microbiota-metabolic organ trilogy to fine-tune physiology. 2019 , 33, 9706-9730		21
111	Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment. 2019 , 43, 127-143		23
110	Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis. 2019 , 42, 1056-1070		19
109	A role of peroxisome proliferator-activated receptor α in non-alcoholic fatty liver disease. 2019 , 124, 528-537		60
108	Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis. 2019 , 64, 1238-1256		12
107	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. 2020 , 41,		56
106	Drug discovery and treatment paradigms in nonalcoholic steatohepatitis. 2020 , 3, e00105		10

105	Adelmidrol protects against non-alcoholic steatohepatitis in mice. 2020 , 393, 777-784	2
104	Current and potential treatments for primary biliary cholangitis. 2020 , 5, 306-315	23
103	New drugs for NAFLD: lessons from basic models to the clinic. 2020 , 14, 8-23	24
102	Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. 2019 , 9,	47
101	Dysregulated lipid metabolism links NAFLD to cardiovascular disease. 2020 , 42, 101092	45
100	Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. 2020 , 9,	28
99	Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?. 2020 , 21,	6
98	Peroxisome Proliferator-Activated Receptors as Molecular Links between Caloric Restriction and Circadian Rhythm. 2020 , 12,	6
97	A triple farnesoid X receptor and peroxisome proliferator-activated receptor γ activator reverses hepatic fibrosis in diet-induced NASH in mice. 2020 , 3,	4
96	Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root. 2020 , 19, 302-314	
95	The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. 2020 , 1115, 154320	28
94	Peroxisome Proliferator-Activated Receptors and Caloric Restriction-Common Pathways Affecting Metabolism, Health, and Longevity. 2020 , 9,	18
93	Palmitoleic acid reduces high fat diet-induced liver inflammation by promoting PPAR- δ -dependent M2a polarization of myeloid cells. 2020 , 1865, 158776	9
92	Gut Dysbiosis and Increased Intestinal Permeability Drive microRNAs, NLRP-3 Inflammasome and Liver Fibrosis in a Nutritional Model of Non-Alcoholic Steatohepatitis in Adult Male Sprague Dawley Rats. 2020 , 13, 351-368	9
91	The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). 2020 , 2020, 3920196	40
90	Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. 2020 , 10, 21117	14
89	The PPAR γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. 2020 , 10, 9330	29
88	Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. 2020 , 21, 1637-1650	19

87	Metabolic liver disease in diabetes - From mechanisms to clinical trials. 2020 , 111S, 154299	39
86	Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. 2020 , 159, 104984	9
85	Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. 2020 , 111S, 154203	46
84	Gegen Qinlian Decoction abates nonalcoholic steatohepatitis associated liver injuries via anti-oxidative stress and anti-inflammatory response involved inhibition of toll-like receptor 4 signaling pathways. 2020 , 126, 110076	15
83	Current and Future Treatments in the Fight Against Non-Alcoholic Fatty Liver Disease. 2020 , 12,	16
82	Novel targeted therapies for the management of liver fibrosis. 2020 , 25, 59-70	8
81	Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. 2020 , 126, 679-704	58
80	Current and new pharmacotherapy options for non-alcoholic steatohepatitis. 2020 , 21, 953-967	17
79	Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. 2021 , 37, 293-311	5
78	Making progress towards a better pathophysiological understanding and more promising therapeutic options for treating non-alcoholic steatohepatitis (NASH)/DASH (dysmetabolism associated steatohepatitis). 2021 , 114, 154333	1
77	Inflammatory Diseases and Vitamin E-What Do We Know and Where Do We Go?. 2021 , 65, e2000097	15
76	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. 2021 , 18, 24-39	67
75	What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease?. 2021 , 11, 232-238	0
74	Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. 2021 , 74, 1188-1199	28
73	Investigational drugs in early phase development for primary biliary cholangitis. 2021 , 30, 131-141	2
72	Rosmarinic acid exerts an antagonistic effect on nonalcoholic fatty liver disease by regulating the YAP1/TAZ-PPAR γ /PGC-1 β signaling pathway. 2021 , 35, 1010-1022	5
71	Berberine induced activation of the SIRT1/LKB1/AMPK signaling axis attenuates the development of hepatic steatosis in high-fat diet-induced NAFLD rats. 2021 , 12, 892-909	9
70	Therapeutic pipeline in nonalcoholic steatohepatitis. 2021 , 18, 373-392	46

69	Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. 2021 , 14, 457-464	6
68	A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis. 2021 , 12, e00327	1
67	Multi-Target Approaches in Metabolic Syndrome. 2020 , 11, 554961	11
66	Fenofibrate Regulates Visceral Obesity and Nonalcoholic Steatohepatitis in Obese Female Ovariectomized C57BL/6J Mice. 2021 , 22,	0
65	Integrative study of diet-induced mouse models of NAFLD identifies PPAR α as a sexually dimorphic drug target. 2021 ,	4
64	Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting. 2021 , 12, 661182	6
63	Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. 2021 , 9, 729	12
62	Saroglitazar, a novel dual PPAR- α/γ agonist, reverses high fat-low protein diet-induced metabolic and cognitive aberrations in C57BL/6J male mice. 2021 , 271, 119191	1
61	Alcoholic and Non-Alcoholic Liver Diseases: Promising Molecular Drug Targets and their Clinical Development. 2021 , 18, 333-353	1
60	Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease. 2021 ,	6
59	Effect of dual PPAR- α/γ agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy. 2021 , 899, 174032	2
58	Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. 2021 , 17, 484-495	32
57	Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients.. 2022 , 12, 435-439	1
56	Anti-diabetic drugs and NASH: from current options to promising perspectives. 2021 , 30, 813-825	2
55	Current and Emerging Approaches for Hepatic Fibrosis Treatment. 2021 , 2021, 6612892	1
54	Saroglitazar, a PPAR- α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. 2021 , 74, 1809-1824	35
53	The pathogenesis, models and therapeutic advances of primary biliary cholangitis. 2021 , 140, 111754	2
52	PPAR α attenuates hepatic inflammation and oxidative stress of non-alcoholic steatohepatitis via modulating the miR-21-5p/SFRP5 pathway. 2021 , 24,	3

51	Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. 2021 , 176, 113888	6
50	Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis. 2021 , 22, 53	3
49	Real-ambient exposure to air pollution exaggerates excessive growth of adipose tissue modulated by Nrf2 signal. 2020 , 730, 138652	9
48	Macrophages in metabolic associated fatty liver disease. 2020 , 26, 1861-1878	14
47	Diallyl Biphenyl-Type Neolignans Have a Pharmacophore of PPAR γ Dual Modulators. 2020 , 28, 397-404	3
46	Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH. 2019 , 7, e8115	7
45	Dual PPAR γ Agonists: Continuing Cardiac Concerns. 2019 , 23, 586-587	1
44	The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD. 2021 , 2021, 6889533	6
43	Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids. 2021 , 144, 112357	2
42	Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. 2021 , 9, 40-50	4
41	The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics. 2021 , 124, 104723	1
40	Pharmacology of NASH. 2021 ,	
39	Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease.. 2022 , 23,	5
38	FXR: structures, biology, and drug development for NASH and fibrosis diseases.. 2022 ,	0
37	Obstructive Sleep Apnea Affects Lacrimal Gland Function.. 2022 , 63, 3	1
36	Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH.. 2022 , 12,	1
35	Investigation of the Effect of Curcumin on Protein Targets in NAFLD Using Bioinformatic Analysis.. 2022 , 14,	0
34	Chronic Liver Diseases: From Development to Novel Pharmacological Therapies.. 2022 ,	

- 33 HA-20 prevents hepatocyte steatosis in metabolic-associated fatty liver disease via regulating Ca relative signalling pathways.. **2022**, 174838
- 32 Effects of cyclocarya paliurus flavonoid extract in non-alcoholic steatohepatitis mice: Intermeshing network pharmacology and in vivo pharmacological evaluation. **2021**, 17, 765
- 31 PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients.. **2022**, 23, 2
- 30 Walnut green husk ethanol extract improves gut microbiota and their metabolites associated with NLRP3 in Non-alcoholic steatohepatitis. 0
- 29 RGS7-ATF3-Tip60 complex promotes hepatic steatosis and fibrosis by directly inducing TNF α **2022**,
- 28 Impact of fenofibrate on NAFLD/NASH: a genetic perspective.. **2022**, 0
- 27 Review: Vascular effects of PPARs in the context of NASH. 0
- 26 Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models. **2022**, 2022, 1-12 1
- 25 Targeting fibrosis: mechanisms and clinical trials. **2022**, 7, 5
- 24 Polypharmacology in Clinical Applications: Metabolic Disease Polypharmacology. **2022**, 199-229
- 23 Are isothiocyanates and polyphenols from Brassicaceae vegetables emerging as preventive/therapeutic strategies for NAFLD? The landscape of recent preclinical findings. **2022**, 13, 8348-8362 1
- 22 N-acetylglucosamine-bearing polymers mimicking O-GlcNAc-modified proteins elicit anti-fibrotic activities in myofibroblasts and activated stellate cells. 0
- 21 The Molecular Mechanisms of Liver Fibrosis and Its Potential Therapy in Application. **2022**, 23, 12572 0
- 20 Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 0
- 19 Mouse models of nonalcoholic steatohepatitis and their application to new drug development. 0
- 18 Human umbilical cord mesenchymal stromal cell-derived exosomes protect against MCD-induced NASH in a mouse model. **2022**, 13, 0
- 17 NAFLD as the metabolic hallmark of obesity. 0
- 16 Chronic high-fat diet induces galectin-3 and TLR4 to activate NLRP3 inflammasome in NASH. **2022**, 109217 0

- 15 Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. **2022**, 46, 829-842 ○
- 14 Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet. **2023**, 23, ○
- 13 Repurposing of Drugs for Cardiometabolic Disorders: An Out and Out Cumulation. **2023**, 55, 7-24 ○
- 12 Hepatic fibrosis: targeting peroxisome proliferator-activated receptor alpha from mechanism to medicines. Publish Ahead of Print, ○
- 11 Baicalein alleviates non-alcoholic fatty liver disease in mice by ameliorating intestinal barrier dysfunction. ○
- 10 Saroglitazar, A Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients with Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis. **2023**, ○
- 9 Recent updates on targeting the molecular mediators of NAFLD. **2023**, 101, 101-124 ○
- 8 Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease. **2023**, 27, 429-449 ○
- 7 PPAR- δ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets. **2023**, 245, 108391 ○
- 6 Saroglitazar, a dual PPAR- α/γ agonist, alleviates LPS-induced hepatic and renal injury in rats. **2023**, 115, 109688 ○
- 5 Emerging Therapeutic Targets for Portal Hypertension. **2023**, 22, 51-66 ○
- 4 Beta-Caryophyllene Modifies Intracellular Lipid Composition in a Cell Model of Hepatic Steatosis by Acting through CB2 and PPAR Receptors. **2023**, 24, 6060 ○
- 3 Current, emerging, and potential therapies for non-alcoholic steatohepatitis. 14, ○
- 2 Deciphering the relational dynamics of AF-2 domain of PAN PPAR through drug repurposing and comparative simulations. **2023**, 18, e0283743 ○
- 1 Tilianin alleviates lipid deposition and fibrosis in mice with nonalcoholic steatohepatitis by activating the PPAR α/γ axis. ○